On a consolidated basis, Dr Reddy s Laboratories net profit dropped 28% to Rs 553.50 crore on 7% increase in revenues to Rs 4,728.40 crore in Q4 March 2021 over Q4 March 2020.
Profit before tax jumped 13% to Rs 807.10 crore in Q4 FY21 as against Rs 714.20 crore in Q4 FY20. EBITDA rose 13.15% to Rs 1,133 crore in Q4 FY21 over Q4 FY20. EBITDA margin stood 24% in Q4 FY21 higher than 22.6% in Q4 FY20.
Revenue in the Global Generics (CG) segment rose 6% to 3873.70 crore in Q4 FY21 over Q4 FY20. The YoY growth was driven by branded markets (India and emerging markets), while Europe was partly offset by decline in North America Generics (NAG).
Dr. Reddy s Laboratories (DRL) along with its subsidiaries announced the launch of Ertapenem for Injection, a therapeutic equivalent generic version of INVANZ.
INVANZ is a trademark of Merck and Co., Inc. The INVANZ brand and generic market had U.S. sales of approximately $205 million MAT for the most recent twelve months ending in March 2021 according to IQVIA Health.
Dr. Reddy s Ertapenem for Injection, 1 g/vial, is available in packs of 10 vials per carton.
Dr. Reddy s Laboratories along with its subsidiaries announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the U.S. Food and Drug Administration (USFDA).
Read more about Dr Reddy s to manufacture baricitinib for Covid -19 treatment in India on Business Standard. Dr. Reddy s Laboratories announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for the manufacture commercialisation of baricitinib in India
Dr Reddy s launches generic Invanz injection in US market
PTI
Hyderabad |
Updated on
Ertapenemis is used to prevent and treat a wide variety of bacterial infections Dr Reddy s Laboratories Ltd, on Wednesday, announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of Invanz approved by the US Food and Drug Administration(FDA). We are pleased to bring this important product to market at this time. We re excited to extend our strategic partnership with Gland Pharma whose hard work, in collaboration with the team at Dr Reddy’s, has enabled the execution of this launch, Marc Kikuchi, CEO, North America Generics, Dr Reddys said in a release.
Dr. Reddy s Labs launches Ertapenem for Injection in the US Market
Mumbai, May 12 (UNI) Dr Reddy s Labs on Wednesday on Wednesday announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the US Food and Drug Administration (USFDA). We are pleased to bring this important product to market at this time, says Marc Kikuchi, CEO, North America Generics, Dr. Reddy s Laboratories. We re excited to extend our strategic partnership with Gland Pharma whose hard work, in collaboration with the team at Dr Reddy s, has enabled the execution of this launch.